Post by Lonza

We have announced plans to expand our payload-linker manufacturing capacity in Visp (CH), including new commercial-scale production capabilities, advanced purification infrastructure, and dedicated analytical and process development laboratories, further strengthening our integrated offering for antibody-drug conjugates (ADCs). By investing in advanced capabilities for highly potent payload-linker synthesis and purification, we are enhancing our ability to support the growing demand for complex ADC therapies and enable flexible, scalable supply from development through to commercial manufacturing. Read more: https://lnkd.in/eRjnJN8x #Lonza #CDMO #ADCs #HPAPI #Oncology #AdvancedSynthesis #PharmaceuticalManufacturing